Company: PAII-WT
Filing Date: 2025-05-29
Form Type: DRS
Source: 0001213900-25-049013
Chunk: 342

Company: Pyrophyte Acquisition Corp. II
Filing Date: 2025-05-29
Form: DRS
Chunk 342
---
| Deferred offering costs paid through the issuance of Class B ordinary shares to Sponsor            |     | $ |  20,000 |   |

The accompanying notes are an integral part of these financial statements.

| F-6 |

| Pyrophyte Acquisition Corp. II              
 Notes to financial statements               
 NOTE 1—ORGANIZATION AND BUSINESS OPERATIONS |

Pyrophyte Acquisition Corp. II (the “Company”) is a blank check company incorporated as a Cayman Islands exempted company on May 1, 2025. The Company was incorporated for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which is referred to as the initial business combination. The Company has not selected any specific business combination target and the Company has not, nor has anyone on its behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with the Company. As of May 5, 2025, the Company had not yet commenced operations. All activity for the period from May 1, 2025 (inception) through May 5, 2025 relates to the Company’s formation and this offering. The Company will not generate any operating revenues until after the completion of its initial business combination, at the earliest. The Company will generate non -operatingincome in the form of interest income on cash and cash equivalents from the proceeds derived from this offering. The Company has selected December 31 as its fiscal year end. The Company’s sponsor is Pyrophyte Acquisition II LLC. The Company’s ability to commence operations is contingent upon obtaining adequate financial resources through an offering of 17,500,000 units at $10.00 per unit (or 20,125,000 units if the underwriters’ over -allotmentoption is exercised in full), which is discussed in Note 3, and the sale of an aggregate of 5,050,000 private placement warrants at a price of $1.00 per unit, to the sponsor, or an affiliate of the sponsor, and independent director nominees, in a private placement that will close simultaneously with the closing of this offering. Each private placement warrant is exercisable to purchase one whole Class A ordinary share at a price of $11.50 per share. The private placement warrants will become exercisable 30 days after the completion of the initial business combination, and will expire five years after the completion of the Company’s